NON-SMALL CELL LUNG CANCER (NSCLC)
Clinical trials for NON-SMALL CELL LUNG CANCER (NSCLC) explained in plain language.
Never miss a new study
Get alerted when new NON-SMALL CELL LUNG CANCER (NSCLC) trials appear
Sign up with your email to follow new studies for NON-SMALL CELL LUNG CANCER (NSCLC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo aims to stall advanced lung cancer
Disease control OngoingThis study tests whether adding olaparib to durvalumab can keep stage IV non-small cell lung cancer from growing longer than durvalumab alone. About 400 adults whose cancer did not worsen after initial chemotherapy and durvalumab will receive either the combination or a placebo a…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated May 01, 2026 16:01 UTC
-
New pill shows promise against Hard-to-Treat cancers
Disease control OngoingThis study tests an experimental oral drug called IMM-1-104 in people with advanced solid tumors that have RAS mutations. The goal is to find safe doses and see if the drug can shrink tumors, either alone or with other treatments. About 209 adults with pancreatic cancer, melanoma…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE1, PHASE2 • Sponsor: Immuneering Corporation • Aim: Disease control
Last updated May 01, 2026 16:01 UTC
-
Can stronger muscles help lung cancer patients beat treatment?
Knowledge-focused ENROLLING_BY_INVITATIONThis study follows 160 adults with lung cancer to see if muscle mass, strength, and function are linked to how well they tolerate treatment and their overall survival. Researchers also want to understand why some patients struggle to complete their therapy. The goal is to use the…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Sponsor: Zealand University Hospital • Aim: Knowledge-focused
Last updated May 01, 2026 16:00 UTC
-
New study tracks side effects of leading lung cancer therapies
Knowledge-focused OngoingThis study observes 300 adults with advanced non-small cell lung cancer whose tumors have very low PD-L1 levels (below 1%). Researchers are tracking side effects and healthcare use from common first-line treatments like nivolumab plus ipilimumab, with or without chemotherapy. The…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated Apr 29, 2026 15:03 UTC